WWA
CRSP icon

WCG Wealth Advisors’s CRISPR Therapeutics CRSP Stock Holding History

WCG Wealth Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$622K Sell
11,400
-36
-0.3% -$1.9K 0.01% 479
2026
Q1 		$544K Buy
11,436
+499
+5% +$26.3K 0.02% 448
2025
Q4 		$574K Buy
+10,937
New +$655K 0.02% 432

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

WCG Wealth Advisors's CRSP Position: Q2 2026 in Review

WCG Wealth Advisors reduced its CRISPR Therapeutics (CRSP) stake by 0.31% in Q2 2026, selling an estimated $1.9K and leaving 11,400 shares worth $622K. The position accounts for 0.01% of the portfolio, ranked #479.

WCG Wealth Advisors first reported a position in CRSP in Q4 2025 and has held it in 3 quarters since. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • WCG Wealth Advisors held 11,400 shares of CRISPR Therapeutics worth $622K as of Q2 2026.
  • WCG Wealth Advisors sold 36 CRISPR Therapeutics shares in Q2 2026, an estimated $1.9K.
  • CRISPR Therapeutics made up 0.01% of WCG Wealth Advisors's portfolio in Q2 2026, its #479 holding.
  • WCG Wealth Advisors first reported a position in CRISPR Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on WCG Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.